News
Dupixent

Dupixent delivers in two skin disease trials

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f

News
Ara Darzi, Baron Darzi of Denham

NHS is in "serious trouble" says Darzi report

A report on the state of the NHS in England by former Labour Health Minister Lord Darzi has concluded that it is in a dire state – which will come as a surprise to nobody – and has problems

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

News
MSD hits a hurdle with its LAG-3 programme

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

Patients

R&D

Partner Content

R&D
9th CDD For Biologics Summit 2024 banner
Partner Content

9th CDD For Biologics Summit 2024

Integrate Computational Biology, Generative AI & Machine Learning to Revolutionize Biologics Drug Discovery & Development